Shiitake & Cardiovascular Health
1 food compound
Eritadenine is the only known food-derived compound to lower cholesterol by blocking S-adenosylhomocysteine hydrolase, a mechanism confirmed by crystal structure analysis.
Yamada et al., Biochemical Pharmacology, 2007
SAHH pathway
distinct from statins, which target the HMG-CoA reductase enzyme
Shiitake-exclusive
not meaningfully present in oyster, reishi, or lion's mane
Strain-dependent
eritadenine content varies widely across shiitake cultivars
Yamada et al., Biochemical Pharmacology, 2007
View as image ↗In 2007, a research team captured something no food scientist had done before with a culinary mushroom compound: they photographed a single molecule from shiitake physically locked onto its target inside a cell. Not inferred from correlations, not estimated from cell assays. Seen at atomic resolution, through X-ray crystallography.
The molecule was eritadenine. The target was an enzyme called S-adenosylhomocysteine hydrolase, shortened to SAHH. SAHH sits at the center of every liver cell's methylation machinery, clearing a toxic waste product called SAH that accumulates whenever cells perform the chemical reactions involved in making membranes and other molecules. When eritadenine jams this enzyme, a cascade of changes follows inside liver cells, ultimately pulling cholesterol out of circulation.
No statin works this way. No fiber supplement works this way. Among the thousands of bioactive compounds found in food, eritadenine is the only one documented to lower cholesterol through SAHH inhibition. And it is found almost exclusively in shiitake mushrooms, which have been part of the human diet for centuries.
This article traces the evidence from crystal structure to liver cells to cholesterol levels, covers what the research says about how much eritadenine is in shiitake and whether cooking destroys it, and is honest about where the animal science ends and the human questions begin. For a broader introduction to shiitake's health profile, see What Is Shiitake Mushroom?.
Key Takeaways
- Eritadenine blocks SAHH (S-adenosylhomocysteine hydrolase), the enzyme that clears the methyl waste product SAH from liver cells. This is a fundamentally different target from statins, which block the cholesterol production enzyme HMG-CoA reductase (Yamada et al., 2007)
- Yamada et al. (2007) determined the crystal structure of eritadenine bound to SAHH, providing atomic-level confirmation that eritadenine fits into the enzyme's active site and blocks it as a competitive inhibitor
- Sugiyama et al. (1995) traced the causal sequence in rat liver cells: SAHH inhibition raises SAH levels, slowing the methylation reactions that convert one liver membrane lipid to another, which in turn reduces plasma cholesterol
- Eritadenine content varies widely across shiitake strains, and drying concentrates it more than fresh. No two commercial shiitake products are guaranteed to contain equal amounts (Enman et al., 2007)
- Eritadenine is water-soluble: boiling leaches it into cooking water, while steaming and sautéing better preserve its concentration in the mushroom tissue (Yao et al., 2023)
- No human trial has tested isolated eritadenine. All human evidence uses whole-food shiitake, which also contains beta-glucans and ergothioneine. Whether dietary doses produce meaningful SAHH inhibition in humans remains an open question
What Eritadenine Is: A Compound Found Almost Exclusively in Shiitake
Eritadenine is a water-soluble nucleoside analog found almost exclusively in shiitake mushrooms (Lentinula edodes). It lowers cholesterol by inhibiting S-adenosylhomocysteine hydrolase (SAHH), the enzyme that clears methyl waste products from liver cells. This shifts liver phospholipid balance and reduces circulating cholesterol through a pathway distinct from statins and unique among food compounds.
Nucleoside analog means eritadenine resembles the molecular building blocks cells use to construct DNA and RNA, but with a structural difference that makes it behave unusually with certain enzymes. Adenosine is one of those building blocks. Eritadenine shares adenosine's core structure but has a different sugar-like chain attached: specifically, the compound is formally known as 2R,3R-dihydroxy-4-[9-adenyl]butyric acid. That modification makes it close enough to fool SAHH into binding it, but different enough that the enzyme cannot complete its normal reaction and move on. The result is a blocked enzyme.
Eritadenine was first isolated from shiitake in 1966. Researchers noticed that animals fed shiitake had lower plasma cholesterol and traced the effect to this compound. The mechanism remained unclear for decades, though it was apparent that eritadenine was not blocking cholesterol synthesis the way statins would later do. Something upstream was happening.
What made eritadenine biochemically remarkable was its specificity. While dozens of plant-derived compounds show broad, nonspecific interactions with cholesterol metabolism, eritadenine acted on a single identifiable enzyme. That enzyme, SAHH, became the focus of subsequent mechanistic research.
Shiitake is essentially the only dietary source. Gil-Ramírez et al. surveyed cholesterol-lowering mechanisms across mushroom species in a 2018 comprehensive review and confirmed eritadenine as essentially specific to Lentinula edodes.[4] Oyster mushrooms produce lovastatin-like compounds. Reishi and lion's mane contain different bioactives with cardiovascular relevance. The SAHH pathway via eritadenine belongs to shiitake.
For more on the full range of shiitake's bioactive compounds, including lentinan and ergothioneine, see Shiitake Bioactive Compounds: Lentinan, Eritadenine, and Beyond.
The Enzyme Nobody Talks About: How SAHH Connects Methylation to Cholesterol
To understand what eritadenine does, you first need to understand a process happening constantly inside every liver cell: methylation.
Methylation is how cells add a chemical tag (one carbon, three hydrogens) to molecules, changing how those molecules behave. One of the most critical methylation reactions in the liver is converting one type of membrane lipid, phosphatidylethanolamine (PE), into another, phosphatidylcholine (PC). These are both phospholipids, meaning they form the backbone of cell membranes. The ratio of PC to PE in liver cell membranes influences how cholesterol moves through and out of those cells.
Every time a methylation reaction occurs, the methyl donor (a molecule called SAM, for S-adenosylmethionine) gives up its methyl group and becomes a waste product called SAH (S-adenosylhomocysteine). SAH is not benign. At high concentrations, it inhibits the same methyltransferase enzymes that are supposed to keep running. The cell's methylation machinery starts to choke on its own waste.
SAHH is the cleanup enzyme. It breaks SAH down into adenosine and homocysteine, keeping SAH levels low enough that methylation can continue normally.
When eritadenine blocks SAHH, SAH builds up. As SAH accumulates, it slows the methylation reactions across the board, including the PE-to-PC conversion in liver membranes. The ratio of PC to PE in those membranes shifts. That shift is where the cholesterol story begins.
The Crystal Structure Proof: Scientists Watched Eritadenine Lock Onto Its Target
Yamada et al. (2007) published the definitive mechanistic study of eritadenine: a crystal structure of the compound bound to SAHH.[1]
Crystal structure determination uses X-ray crystallography to map the exact three-dimensional position of every atom in a molecule. When a research team can crystallize two molecules bound together, they produce an atomic-resolution image of their interaction. This is not a model or an inference. It is a direct observation of molecular geometry.
What the crystal structure showed: eritadenine fits into the same binding pocket in SAHH where the enzyme's normal substrate, SAH, would bind. The structural similarity to adenosine (which is part of SAH's own structure) is what allows this. But eritadenine cannot be processed and released like SAH can. It occupies the binding pocket and stays there, blocking the enzyme from doing its job.
This makes eritadenine what biochemists call a competitive inhibitor. It competes with the real substrate (SAH) for the enzyme's binding site. When eritadenine concentration is low relative to SAH, SAH wins most competitions and the enzyme keeps working. As eritadenine concentration rises, it wins more often, and SAHH inhibition increases. The degree of effect scales with dose and with how much SAH is present.
This crystal structure publication is also why the mechanistic case for eritadenine stands apart from most food-derived cholesterol-lowering claims. Most such claims rest on cell or animal studies showing a correlation between a compound and lower cholesterol, with the mechanism inferred. Eritadenine has something stronger: direct structural evidence of how it physically interacts with its molecular target.
For context on how this compares to other mushroom cholesterol mechanisms, see Mushrooms That Lower Cholesterol: What the Research Shows.
Inside Liver Cells, Step by Step: The Sequence That Drops Plasma Cholesterol
Sugiyama et al. (1995) traced the sequence of events inside rat liver cells after eritadenine exposure.[2] This established not just that eritadenine lowers cholesterol, but in what order each change occurs, proving the relationship is causal rather than coincidental.
The sequence Sugiyama documented:
First, eritadenine inhibits SAHH, and SAH levels rise in liver cells. This is the direct effect.
Second, rising SAH slows the methylation reaction that converts PE to PC in liver cell membranes. The PC-to-PE ratio in those membranes shifts. This is the upstream cellular change.
Third, the altered phospholipid balance in liver membranes changes how those cells process and export cholesterol into the bloodstream. Plasma cholesterol levels fall. This is the downstream clinical outcome.
The critical insight from this sequence is that eritadenine does not touch cholesterol directly. It does not block any enzyme in the cholesterol synthesis pathway. It does not bind cholesterol or bile acids in the gut. It works entirely through phospholipid membrane remodeling, which then propagates downstream to affect cholesterol.
Statins work in a categorically different place. They block HMG-CoA reductase, the enzyme that catalyzes an early step in cholesterol synthesis from scratch. Block that enzyme and the body simply produces less cholesterol. Eritadenine leaves cholesterol synthesis completely untouched. It changes the liver's membrane environment, and that environmental change alters how cholesterol moves through the system.
This separation of mechanisms has an interesting implication: eritadenine and statins are not targeting the same process. In theory, they could have complementary rather than redundant effects. That combination has not been studied in humans, but the mechanistic independence is real.
For the human clinical evidence on what whole-food shiitake does to LDL in practice, see How Shiitake Lowers LDL Cholesterol: Clinical Evidence.
How Much Eritadenine Is in Shiitake, and Why Strain Matters
Knowing the mechanism is one thing. Knowing how much eritadenine a person actually consumes when eating shiitake is another.
Enman et al. (2007) addressed this directly, measuring eritadenine content across multiple shiitake strains using validated quantification methods.[3] Two findings stood out.
First, eritadenine content varies widely across shiitake strains. The variation between cultivars grown under similar conditions is not trivial. Different strains produce meaningfully different concentrations of eritadenine in their fruiting bodies. The shiitake sold at a grocery store may come from a strain with relatively high eritadenine content, or from one with relatively low content. There is no way to tell from the label.
Second, drying concentrates eritadenine. When water is removed from the mushroom, the same quantity of eritadenine now occupies a smaller mass of tissue. Dried shiitake contains more eritadenine per gram than fresh shiitake, not because more was produced, but because the water is gone. This is why dried preparations are often used in research, and why comparing fresh versus dried servings by weight will give misleading impressions of dose.
This variation in natural content creates a genuine problem for understanding the dose-response relationship. If two studies use different shiitake strains or different processing methods and produce different results, differences in eritadenine content are a plausible contributor to that variation, not just measurement noise.
There is no commercial isolated eritadenine supplement. The compound exists only as a component of whole shiitake products, whether fresh, dried, or extracted. This makes standardized dosing studies of eritadenine specifically, separated from the mushroom's other bioactives, difficult to conduct.
The Second Pathway: How Shiitake's Beta-Glucans Hit Cholesterol Through a Completely Different Route
Eritadenine gets most of the mechanistic attention in discussions of shiitake and cholesterol, but it is not the only pathway at work.
Shiitake also contains beta-glucans, a class of soluble fiber. In the small intestine, beta-glucans bind bile acids, the cholesterol-derived molecules the liver secretes to help digest dietary fat. Normally, the body reabsorbs most bile acids in the lower intestine and recycles them. When beta-glucans bind the bile acids and carry them out in stool instead, the liver must synthesize new ones. That synthesis draws on circulating cholesterol, reducing plasma levels.
Palanisamy et al. (2014) tested shiitake beta-glucan fractions directly for bile acid binding capacity in vitro and confirmed significant binding activity.[5] This is mechanistically identical to how oat beta-glucan works, the same mechanism behind many cholesterol-lowering food claims, but delivered from a fungal source with a different beta-glucan structural profile.
Gil-Ramírez et al. (2018) mapped all three cholesterol-lowering pathways found across edible mushroom species in the most comprehensive comparative analysis available.[4]
The three pathways:
- Eritadenine SAHH inhibition and phospholipid remodeling: specific to shiitake
- Beta-glucan bile acid sequestration: found broadly across many mushroom species
- Lovastatin-like HMG-CoA inhibition: found primarily in oyster mushrooms (Pleurotus species)
Shiitake uniquely combines the first and second mechanisms. Oyster mushrooms have the second and third. No other common edible mushroom has the SAHH pathway. When people eat shiitake for cardiovascular benefit, both eritadenine and beta-glucans are likely contributing, through completely separate routes. The relative contribution of each in human consumers has not been teased apart.
For a comparison of how reishi's triterpene compounds approach cholesterol through yet another pathway, see Reishi and Cholesterol Management: Triterpene Mechanisms.
Does Cooking Destroy Eritadenine? The Temperature and Water Problem
Eritadenine is water-soluble. This is the central practical fact for anyone thinking about how to prepare shiitake.
Yao et al. (2023) measured bioactive compound retention in shiitake across different cooking methods.[7] Boiling submerges the mushroom in water, and water-soluble compounds follow the water. Eritadenine leaches out of the mushroom tissue and into the cooking liquid. If that liquid is discarded, the eritadenine goes with it. Steaming heats the mushroom without submersion, so water-soluble compounds remain concentrated in the tissue. Sautéing in oil avoids water contact entirely, though the high heat of direct pan contact introduces different considerations.
The practical takeaway from Yao's work: steaming and sautéing preserve more eritadenine than boiling and discarding the water. If you are boiling shiitake as part of a soup or broth, the eritadenine leaches into the liquid but stays in the dish. The issue is specifically boiling and then draining.
Zhang et al. (2021) added a second dimension to this question.[6] Their work examined how eritadenine is synthesized inside shiitake during cultivation. Heat stress during growing affects how much eritadenine the mushroom produces before it is harvested. Temperature during cultivation and the availability of purine precursors both modulate eritadenine synthesis. This is more relevant to growers and producers than to consumers, but it adds to the picture of why eritadenine content is variable at every stage: growing conditions, strain genetics, drying, and cooking method all shape how much reaches the person eating the mushroom.
The practical upshot is not that cooking defeats the purpose of eating shiitake. Most of the other bioactives in shiitake, including beta-glucans and ergothioneine, are more heat-stable. Eritadenine specifically deserves some consideration of cooking method if maximizing its intake is the goal. Using cooking liquid and preferring steaming or sautéing over boiling-and-discarding makes sense given the water-solubility data.
For a detailed look at how daily consumption patterns and preparation methods connect to cardiovascular biomarker outcomes in clinical trials, see Daily Shiitake Consumption and Cardiovascular Biomarkers.
The Human Evidence Gap: No Isolated Eritadenine Trial Exists Yet
Here is the honest state of the evidence.
The mechanistic case for eritadenine is exceptionally well-documented for a food compound. The crystal structure proof confirms SAHH binding at atomic resolution (Yamada 2007). The causal sequence of events inside liver cells is established in animal models (Sugiyama 1995). The in vitro confirmation of beta-glucan bile acid binding as a second independent mechanism is solid (Palanisamy 2014). A comprehensive comparative review establishes shiitake's uniqueness among edible mushrooms in having the SAHH pathway (Gil-Ramírez 2018).
What does not exist is a human trial testing isolated eritadenine at defined doses.
Every human study of shiitake and cholesterol has used whole shiitake mushrooms or whole-food shiitake products. These deliver eritadenine alongside beta-glucans, ergothioneine, and dozens of other compounds. You cannot read the results of those trials and attribute the observed effects specifically to eritadenine. The mechanism points to it. The animal data support it. But a human trial isolating eritadenine's specific contribution has not been conducted.
The dosing question is genuinely unresolved. In rat studies, eritadenine at approximately 0.005% of dietary intake produced measurable cholesterol-lowering effects. Translating that to a human equivalent requires assumptions about body size, absorption, and bioavailability that have not been tested in humans. Whether a typical culinary serving of shiitake, or even a daily shiitake supplementation protocol, delivers enough eritadenine to meaningfully inhibit SAHH in human liver cells is not known.
This is not a reason to dismiss the mechanism. The SAHH pathway is real and well-documented. The crystal structure is real. Animal effects are consistent across multiple study designs. But stating that eating shiitake definitively lowers human LDL cholesterol specifically because of eritadenine gets ahead of what the evidence supports.
The honest framing: eritadenine has the most mechanistically rigorous documentation of any food compound for SAHH-mediated cholesterol lowering, and shiitake is the only practical dietary source. Whether the amounts achievable through culinary or supplemental shiitake use translate to meaningful SAHH inhibition in humans is an open question that warrants a well-designed clinical trial.
For the broader cardiovascular picture including the human evidence that does exist for whole-food shiitake, see Shiitake and Cholesterol: Eritadenine's Unique Mechanism and Shiitake and Heart Disease Prevention: Research Review.
The Bottom Line
Eritadenine is the only known food-derived compound to lower cholesterol via S-adenosylhomocysteine hydrolase (SAHH) inhibition, and shiitake mushrooms are its only meaningful dietary source. The mechanism is exceptionally well-documented at the molecular level: crystal structure analysis confirmed direct SAHH binding in 2007, and rat studies established the causal sequence from phospholipid membrane changes to plasma cholesterol reduction in 1995. The gap between mechanistic clarity and human clinical evidence remains real. No isolated eritadenine supplement trial exists, and whether dietary amounts achievable from shiitake consumption produce meaningful SAHH inhibition in humans has not been established.
Frequently Asked Questions
Sources & References
- 1RTHM-00238·Yamada, Taro et al. (2007). “Structure and function of eritadenine and its 3-deaza analogues: potent inhibitors of S-adenosylhomocysteine hydrolase and hypocholesterolemic agents..” Biochemical pharmacology.Study breakdown →PubMed →↩
- 2RTHM-00045·Sugiyama, K et al. (1995). “Hypocholesterolemic action of eritadenine is mediated by a modification of hepatic phospholipid metabolism in rats..” The Journal of nutrition.Study breakdown →PubMed →↩
- 3RTHM-00211·Enman, Josefine et al. (2007). “Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (Lentinus edodes)..” Journal of agricultural and food chemistry.Study breakdown →PubMed →↩
- 4RTHM-00510·Gil-Ramírez, Alicia et al. (2018). “Molecular actions of hypocholesterolaemic compounds from edible mushrooms..” Food & function.Study breakdown →PubMed →↩
- 5RTHM-00342·Palanisamy, Marimuthu et al. (2014). “Pressurized water extraction of β-glucan enriched fractions with bile acids-binding capacities obtained from edible mushrooms..” Biotechnology progress.Study breakdown →PubMed →↩
- 6. Source details for this reference are not yet available.
- 7. Source details for this reference are not yet available.